EFFICIENCY OF TREATMENT FOR LATENT IRON DEFICIENCY IN PREGNANT WOMEN WITH CHRONIC PYELONEPHRITIS

Objective. To comparatively estimate the time course of changes in the functional, transport, and iron regulatory funds of iron metabolism in pregnant women with latent iron def iciency (LID) and chronic pyelonephritis treated and untreated with iron III hydroxide polymaltose complex. Subjects and methods. The trial enrolled 119 pregnant women, 52 of whom had LID and chronic pyelonephritis (Group 1) and 67 LID patients without urinary tract infection (UTI) (Group 2). According to the presence or absence of LID treatment, Group 1 and 2 patients were divided into subgroups: 1A) 24 pregnant women with chronic pyelonephritis and treated LID; 1B) 28pregnant women with chronic pyelonephritis and untreated LID; 2A) 31 pregnant women with non- UTI and treated LID; 2B) 36 pregnant women with non-UTI and untreated LID. The treatment or selective prevention of LID involved the use of iron preparations in the pregnant women with LID diagnosed by laboratory tests for iron metabolic parameters. Results. The time course of changes in the functional, transport, and iron regulatory funds of iron metabolism (hemoglobin, red blood cells, packed cell volume, red blood cell indices, serum iron, soluble transferrin receptors, iron transferrin saturation coefficient, erythropoietin (EPO), and its production adequacy ratio (PAR) was studied in the pregnant women with LID and chronic pyelonephritis treated and untreated with iron III hydroxide polymaltose complex. The efficiency of selective prevention of manifest iron deficiency (LID treatment in the pregnant women) depended on the level of endogenous EPO. In the pregnant women with LID and chronic pyelonephritis who had an EPO PAR of 40.8, the therapeutic efficiency was 70.9%, which was significantly lower than that (93.55%) in the LID patients without chronic pyelonephritis who had an EPO PAR of >0.8. Conclusion. LID treatment in the pregnant women prevents manifest iron deficiency, causing the incidence of placental insufficiency and fetal growth retardation to reduce.

pregnancy, latent iron deficiency, chronic pyelonephritis, treatment, selective prevention of manifest irondeficiency, solubletransferrinreceptors, serumerythropoietin, erythropoietinproductionadequacyratio, iron III hydroxide polymaltose complex